secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001171843-23-000154
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst prelim 2022 ORLADEYO rev $251.6M (+105% YoY); FY23 guide ≥$320M; BCX10013 data positive
--------------------------------------------------------------------------------

- Prelim 2022 ORLADEYO net rev $251.6M (+105% YoY); Q4 rev $70.7M (+53% YoY).
- FY2023 ORLADEYO net rev guidance no less than $320M; company expects peak sales of $1B.
- Phase1 data for BCX10013 (oral Factor D inhibitor): >97% AP suppression at 110 mg single dose, safe/well-tolerated.
- Advancing BCX10013 into patient studies mid-2023 for PNH and IgAN; expanding complement platform to C2 targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/0001171843-23-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323000154/f8k_010923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer